Sushil Patel
Sushil Patel is on the board of Revolution Medicines, Inc. and Chief Strategy Officer of Replimune Group, Inc.
Dr. Patel previously held the position of Vice President-Franchise & Head-Oncology at Genentech, Inc.
Dr. Patel received a graduate degree from Imperial College London, a doctorate from the University of London and an undergraduate degree from the University of Warwick.
Transactions
Date
Transaction
Value
| 06/08/2023 | 5,200 | Award at $0 per share. | 0 |
| 06/16/2022 | 10,500 | Award at $0 per share. | 0 |
